Weigert Günther, Zawinka Claudia, Resch Hemma, Schmetterer Leopold, Garhöfer Gerhard
Department of Clinical Pharmacology, Medical University of Vienna, Austria.
Invest Ophthalmol Vis Sci. 2006 Mar;47(3):1096-100. doi: 10.1167/iovs.05-1174.
Intravenous administration of histamine causes an increase in choroidal blood flow (ChBF) and retinal vessel diameters in healthy subjects. The receptor mediating this response has not yet been identified. The present study was undertaken to clarify whether H1 receptor blockade with diphenhydramine affects the hemodynamic response of histamine in the choroid and the retina.
A randomized, double-masked, placebo-controlled, two-way crossover study was performed in 18 healthy, male, nonsmoking subjects. Histamine (0.32 microg/kg per minute over 30 minutes) was infused intravenously in the absence (NaCl as placebo) or presence of the H1 blocker diphenhydramine (1.0 mg/min over 50 minutes). Ocular hemodynamic parameters, blood pressure, and intraocular pressure were measured before drug administration, after infusion of diphenhydramine or placebo, and after co-infusion of histamine. Subfoveal ChBF and fundus pulsation amplitude (FPA) were measured with laser Doppler flowmetry and laser interferometry, respectively. Retinal arterial and venous diameters were measured with a retinal vessel analyzer. Retinal blood velocity was assessed with bidirectional laser Doppler velocimetry.
Administration of histamine caused a decrease in mean arterial pressure by -4% +/- 9% (ANOVA P = 0.01). This effect was blunted by coadministration of diphenhydramine (ANOVA, P = 0.04). Histamine significantly increased FPA and subfoveal ChBF. Coadministration of diphenhydramine significantly reduced this effect (ANOVA; FPA P = 0.001, ChBF P = 0.049). Histamine significantly increased retinal arterial diameter by +3.5% +/- 4.5% and retinal venous diameter by +3.7% +/- 2.8%. Again, coadministration of diphenhydramine significantly reduced the vasodilative effect to +0.3% +/- 5.5% in retinal arteries (ANOVA, P = 0.00006) and to +0.9% +/- 2.5% in retinal veins (ANOVA, P = 0.004).
The present data confirm that histamine increases ChBF and retinal vessel diameters in healthy subjects. Administration of the H1 receptor blocker diphenhydramine significantly reduced histamine-induced changes in ocular perfusion parameters. These results strongly indicate that in the retina and choroid, H1 receptors are involved in the histamine-mediated hemodynamic effects in vivo.
静脉注射组胺可使健康受试者的脉络膜血流量(ChBF)增加,视网膜血管直径增大。介导这种反应的受体尚未确定。本研究旨在阐明用苯海拉明阻断H1受体是否会影响组胺对脉络膜和视网膜的血流动力学反应。
对18名健康、男性、不吸烟的受试者进行了一项随机、双盲、安慰剂对照的双向交叉研究。在不存在(用生理盐水作为安慰剂)或存在H1受体阻滞剂苯海拉明(50分钟内1.0毫克/分钟)的情况下,静脉输注组胺(30分钟内0.32微克/千克每分钟)。在给药前、输注苯海拉明或安慰剂后以及同时输注组胺后,测量眼部血流动力学参数、血压和眼压。分别用激光多普勒血流仪和激光干涉仪测量黄斑下ChBF和眼底搏动幅度(FPA)。用视网膜血管分析仪测量视网膜动脉和静脉直径。用双向激光多普勒测速仪评估视网膜血流速度。
输注组胺使平均动脉压降低了-4%±9%(方差分析P = 0.01)。同时给予苯海拉明可减弱这种作用(方差分析,P = 0.04)。组胺显著增加了FPA和黄斑下ChBF。同时给予苯海拉明可显著降低这种作用(方差分析;FPA P = 0.001,ChBF P = 0.049)。组胺使视网膜动脉直径显著增加了+3.5%±4.5%,视网膜静脉直径增加了+3.7%±2.8%。同样,同时给予苯海拉明可使视网膜动脉的血管舒张作用显著降低至+0.3%±5.5%(方差分析,P = 0.00006),视网膜静脉的血管舒张作用降低至+0.9%±2.5%(方差分析,P = 0.004)。
目前的数据证实组胺可增加健康受试者的ChBF和视网膜血管直径。给予H1受体阻滞剂苯海拉明可显著降低组胺引起的眼部灌注参数变化。这些结果强烈表明,在视网膜和脉络膜中,H1受体参与了组胺介导的体内血流动力学效应。